We are one of the leading generic pharmaceutical companies in Central Eastern Europe, our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of Servier, a global pharmaceutical group governed by a Foundation. In the 2021/2022 business year Egis Group generated net sales of EUR 577.6 million. Besides Hungary, we sell our products under Egis’ brand names in 17 countries through our network of subsidiaries and representative offices. Our products (active ingredients, tablets, injections, galenic formulations etc.) are available in 62 countries in total through our network of subsidiaries and representative offices or partners. Our focus lies on treating diseases of the cardiovascular and central nervous systems and we also provide modern treatment solutions in the fields of oncology and women’s health. In 2013, we launched our first biosimilar monoclonal antibody (mAb) product, it was also the first mAb in the European Union. Since then, we launched 3 more biosimilar drugs. As one of the companies in the CEE region committed to innovation, we devote more than EUR 45 million yearly to R&D. Our research and development activities focus on high-quality, value-added branded generic products. In the last 20 years, we have invested more than EUR 770 million in improvements in Hungary: we modernized the complete process of finished product manufacturing and established state-of-the-art R&D centres. In Budapets the development of drugs substances and finished products having significant biological activity in very small doses has become possible and the comprehensive modernization of the traditional technology of active ingredient manufacturing has been completed. Large-scale developments at our site in Körmend: inauguration of a new galenic plant (Sept 2019); the major extension of the packaging plant was completed (1st phase) and capacity to manufacture special medicines - typically oncology products - was established (both 2021 autumn).